HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins.

AbstractPURPOSE:
To evaluate the prognostic significance and correlation with staging and degree of cell differentiation of the tumoral expression of the proteins c-erbB-2 and E-cadherin, in patients with colorectal adenocarcinoma.
METHODS:
The study included 117 patients with an average age of 63.1 years and an average follow-up duration of 28.1 months. The disease-free interval, survival, incidence of recurrence and specific mortality were evaluated. c-erbB-2 anti-oncoprotein antibodies (Dako) were utilized via the streptavidin-biotin technique. Samples were considered to be positive for c-erbB-2 if 10% or more of the tumor cell membranes were stained. The anti-E-cadherin antibodies (Dako), evaluated this protein and is considered positive, if 50% or more of the cell membranes were stained. Statistical analysis was performed using Pearson's chi-squared test, Fisher's exact test, Kaplan-Meier's estimator, the log-rank test and Wilcoxon's test (Breslow version), setting the level of statistical significance at 5% (p<0.05).
RESULTS:
52 of 108 patients studied for c-erbB-2 were positive (48.1%), 47 of 93 patients studied for E-cadherin were negative (50.5%). These data do not express any correlation with TNM (tumor, node and metastasis) staging and the degree of cell differentiation or with the tumor recurrence rate. The disease-free interval among patients who were positive for c-erbB-2 and negative for E-cadherin was 68.0 months and did not differ from those with c-erbB-2 negative and E-cadherin positive (55.0 months--p = 0.5510). The average survival among patients positive for c-erbB-2 and negative for E-cadherin was 75 months without statistical significance difference with the other group (61 months--p = 0.5256). Specific mortality occurred in 20.0% of the cases and did not correlate with the expression of c-erbB-2 (p=0.446), E-cadherin (p=0.883).
CONCLUSION:
The tumoral expression of c-erbB-2 and E-cadherin did not demonstrate a correlation with the staging and degree of cell differentiation, and it did not present prognostic value regarding disease recurrence, disease-free interval, survival and specific mortality among patients with colorectal adenocarcinoma.
AuthorsEliane C Jesus, Delcio Matos, Ricardo Artigiani, Angela F L Waitzberg, Alberto Goldenberg, Sarhan Sydney Saad
JournalActa cirurgica brasileira (Acta Cir Bras) 2005 Nov-Dec Vol. 20 Issue 6 Pg. 422-7 ISSN: 0102-8650 [Print] Brazil
PMID16302076 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Cadherins
  • Neoplasm Proteins
  • Receptor, ErbB-2
Topics
  • Adenocarcinoma (chemistry, mortality, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (immunology)
  • Brazil (epidemiology)
  • Cadherins (analysis)
  • Colorectal Neoplasms (chemistry, mortality, pathology)
  • Epidemiologic Methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Proteins (analysis)
  • Neoplasm Staging
  • Prognosis
  • Receptor, ErbB-2 (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: